HOVON 185: Pharmacokinetic boosting of ibrutinib with ritonavir in patients with chronic lymphocytic leukemia, lymphoplasmacytic- and mantle cell lymphoma
This study is testing a new way to give ibrutinib, a targeted medicine used to treat slow-growing blood cancers such as chronic lymphocytic leukaemia, mantle cell lymphoma, and lymphoplasmacytic lymphoma. Normally, the body breaks ibrutinib down quite quickly. In this trial, researchers are adding a second medicine called ritonavir. Ritonavir acts as a 'booster' by slowing down how the liver processes ibrutinib. This means a smaller dose of ibrutinib could stay in the body at the right levels to fight cancer. The trial will check drug levels in the blood, watch for side effects, and track how well the cancer responds over time. Researchers also want to see if this approach maintains quality of life and helps reduce overall treatment costs. Taking part is completely voluntary, and participants are closely monitored by hospital specialists throughout.
At a glance
What is this study about?
Chronic lymphocytic leukaemia, mantle cell lymphoma, and lymphoplasmacytic lymphoma are types of blood cancer that affect white blood cells. A targeted medicine called ibrutinib is often used to treat these conditions. It works by blocking signals that cancer cells need to survive and multiply. While ibrutinib works well, patients usually need to take high doses every day, which can be costly and sometimes cause side effects.
This trial is looking at a technique called 'drug boosting'. The researchers are adding a small dose of another approved medicine, ritonavir, alongside ibrutinib. Ritonavir slows down the liver enzymes that break ibrutinib down. By doing this, ibrutinib stays in the bloodstream for longer, meaning patients might only need a lower daily dose to get the exact same benefit.
The study takes place in two parts. First, doctors take blood samples to measure exactly how much ibrutinib stays in the blood when taken with ritonavir. In the second part, participants continue the combination treatment while doctors check how well it keeps the cancer under control, monitor any side effects, and measure quality of life. If successful, this method could help make cancer treatments more efficient and cost-effective for health services like the NHS.
Key takeaways
- Tests combining ibrutinib with ritonavir to keep drug levels steady using smaller doses.
- Aimed at adult men with CLL, mantle cell lymphoma, or lymphoplasmacytic lymphoma.
- Involves daily oral tablets, blood tests, and regular hospital monitoring visits.
- Could help reduce medication costs and improve how cancer drugs are prescribed.
- Participation is completely voluntary and you can stop at any time.
Who may be eligible?
This study is open to adult men who have been diagnosed with chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), or lymphoplasmacytic lymphoma (LPL). Participants must be at least 18 years of age and in need of treatment for their blood condition.
To take part, you must be able to swallow tablets and be well enough to attend regular hospital appointments for check-ups and blood tests. You will also need reasonable liver and kidney function so your body can safely handle the study medications.
You may not be eligible if you are taking other medications that strongly interact with ritonavir or ibrutinib, or if you have certain other serious medical conditions. Your hospital specialist will review your full medical history and recent blood test results to confirm whether this trial is safe and suitable for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am a man aged 18 or older.
- I have been diagnosed with CLL, mantle cell lymphoma, or lymphoplasmacytic lymphoma.
- My doctor has advised that I need treatment for my blood cancer.
- I am able to swallow tablets each day.
- I am willing and able to travel to the hospital for scheduled tests and visits.
What does participation involve?
If you join the trial, you will take ibrutinib and ritonavir tablets by mouth each day at home. During the early 'run-in' phase, you will have regular blood tests taken over specific time periods to measure the drug levels in your body. In the longer 'extension' phase, you will attend hospital clinic visits for routine check-ups, blood tests, and scans to see how your cancer is responding. You will also be asked to fill out short questionnaires about your daily wellbeing and any symptoms you notice. The study lasts for at least a year (52 weeks), and your medical team will continue to follow your health during and after the trial.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What does 'boosting' a medicine mean?
Boosting means using a second medicine (in this case, ritonavir) to slow down how fast your body clears the main medicine (ibrutinib). This keeps the cancer drug working in your bloodstream longer, even at a lower dose.
Are the study medicines new or experimental?
Both ibrutinib and ritonavir are already approved and widely used in medicine. What is new in this trial is testing them together at specific doses for these blood cancers.
Will taking part cost me anything?
No, the trial medicines and study-related tests are provided free of charge. You may also be able to get help with travel expenses for your hospital visits.
What happens if I experience unpleasant side effects?
Your trial team will monitor you closely at every visit. If you have bothersome side effects, your doctor can adjust your doses, offer treatments to help with symptoms, or pause the study medicines.
Can I leave the study if I change my mind?
Yes. You have the right to withdraw from the trial at any point, for any reason. Your doctor will discuss alternative, standard treatment options with you immediately.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.